Identification
- Generic Name
- MVA-BN-brachyury-TRICOM vaccine
- DrugBank Accession Number
- DB17424
- Background
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3. These immune-enhancing co-stimulatory molecules exert immunostimulatory and antineoplastic actions.1 MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)âBrachyury booster vaccine.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- MVA-BN-Brachyury
- MVA-BN-Brachyury Prime Vaccine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GD1ZWN2I2Y
- CAS number
- Not Available
References
- General References
- National Cancer Institute: MVA-BN-brachyury-TRICOM vaccine [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Withdrawn Treatment Adenocarcinoma of Prostate 1 1 Completed Treatment Metastatic Solid Neoplasm 1 1 Completed Treatment Safety Issues 1 1 Not Yet Recruiting Treatment Breast Cancer / Lung Cancer / Ovarian Cancer / Prostate Cancer / Tumors (Others) 1 1, 2 Active Not Recruiting Treatment Advanced Solid Tumors / Metastatic Prostate Cancer / Neoplasms of the Prostate / Prostate Cancer / Solid Tumors 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at January 06, 2023 16:42 / Updated at January 07, 2023 01:39